Zoetis Inc. $ZTS Shares Sold by Aquatic Capital Management LLC

Aquatic Capital Management LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 44.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,842 shares of the company’s stock after selling 47,121 shares during the quarter. Aquatic Capital Management LLC’s holdings in Zoetis were worth $8,610,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of ZTS. Halbert Hargrove Global Advisors LLC lifted its holdings in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares during the last quarter. Financial Consulate Inc. acquired a new position in shares of Zoetis in the 3rd quarter worth approximately $39,000. SJS Investment Consulting Inc. grew its stake in shares of Zoetis by 1,606.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after purchasing an additional 257 shares during the last quarter. TruNorth Capital Management LLC bought a new stake in shares of Zoetis in the 3rd quarter worth approximately $42,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Zoetis in the 3rd quarter worth approximately $46,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ZTS has been the subject of a number of research reports. KeyCorp began coverage on shares of Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating for the company. UBS Group set a $136.00 price target on Zoetis in a report on Thursday, January 29th. HSBC set a $140.00 price objective on Zoetis in a research report on Wednesday, December 10th. Weiss Ratings raised Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday. Finally, BTIG Research reaffirmed a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

Zoetis stock opened at $115.62 on Monday. Zoetis Inc. has a fifty-two week low of $114.47 and a fifty-two week high of $172.23. The firm’s 50 day simple moving average is $125.34 and its 200-day simple moving average is $131.58. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The company has a market cap of $48.81 billion, a P/E ratio of 19.21, a price-to-earnings-growth ratio of 1.76 and a beta of 0.95.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter in the prior year, the firm earned $1.40 EPS. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.